Regulation of cellular functions by two human Polyomaviruses

两种人类多瘤病毒对细胞功能的调节

基本信息

  • 批准号:
    9088664
  • 负责人:
  • 金额:
    $ 23.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-02-01 至 2018-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Polyomaviruses have small genomes and their coding capacity is very limited. In order to encode for functions needed in viral DNA replication, transcriptional control, and the manipulation of host functions, polyomaviruses express a series of alternatively spliced forms of their early mRNA that encode T antigens. All polyomaviruses encode a multifunctional large T antigen (LT) and most encode a small T antigen (ST), plus a series of additional poorly characterized early proteins. Of the thirteen polyomaviruses that have been isolated from humans, several express both an LT and ST that appear to be similar in function to those of the well-studied Simian virus 40 (SV40). However, other human polyomaviruses are quite distinct from SV40 regarding both the structure and biological activities of their LT and ST proteins. These include the recently discovered New Jersey polyomavirus (NJPyV) and Human polyomavirus 9 (HuPyV9). In this exploratory application we seek to uncover the unique biology of the NJPyV and HuPyV9 T antigens. Specifically, we will determine whether an alternative T antigen (AT) encoded by NJPyV is in fact an authentic middle T antigen (MT). Thus, far the only polyomaviruses that express a MT protein, murine polyomavirus and hamster polyomavirus, infect rodents. Thus, finding a human virus that expresses a MT would be very novel and suggest unique host manipulation functions. In addition, we will determine how the LT and ST from LPV, a primate polyomavirus closely related to HuPyV9- are able to independently immortalize cells and induce cell proliferation, and will also determine the molecular basis for the robust synergistic action of these proteins. Rather than recapitulate the well-trodden path that has been used to characterize T antigens in the past, we have developed new strategies designed to efficiently identify cellular pathways altered by T antigens from RNA-Seq data, and then to couple this approach with more traditional genetics and proteomics. Using this strategy, we can determine whether HuPyV9 alters the same cellular pathways as SV40 and other similar polyomaviruses, or if this virus manipulates cellular functions by novel mechanisms.
 性状(由申请方提供):多瘤病毒基因组较小,编码能力非常有限。为了编码病毒DNA复制、转录控制和操纵宿主功能所需的功能,多瘤病毒表达一系列编码T抗原的其早期mRNA的可变剪接形式。所有多瘤病毒编码一个多功能的大T抗原(LT),大多数编码一个小T抗原(ST),加上一系列额外的特征不明显的早期蛋白质。在已经从人类分离的13种多瘤病毒中,有几种表达LT和ST,它们的功能似乎与研究充分的猿猴病毒40(SV 40)相似。然而,其他人多瘤病毒在其LT和ST蛋白的结构和生物活性方面与SV 40完全不同。其中包括最近发现的新泽西多瘤病毒(NJPyV)和人类多瘤病毒9(HuPyV 9)。在这种探索性应用中,我们试图揭示NJPyV和HuPyV 9 T抗原的独特生物学。具体而言,我们将确定由NJPyV编码的替代T抗原(AT)是否实际上是真正的中间T抗原(MT)。因此,迄今为止仅有的表达MT蛋白的多瘤病毒(鼠多瘤病毒和仓鼠多瘤病毒)感染啮齿动物。因此,发现表达MT的人类病毒将是非常新颖的,并表明独特的宿主操纵功能。此外,我们将确定LPV(一种与HuPyV 9密切相关的灵长类多瘤病毒)的LT和ST如何能够独立地使细胞永生化并诱导细胞增殖,并且还将确定这些蛋白质的强大协同作用的分子基础。我们没有重述过去用于表征T抗原的成熟途径,而是开发了新的策略,旨在从RNA-Seq数据中有效地识别T抗原改变的细胞途径,然后将这种方法与更传统的遗传学和蛋白质组学结合起来。使用这种策略,我们可以确定HuPyV 9是否改变了与SV 40和其他类似多瘤病毒相同的细胞途径,或者这种病毒是否通过新的机制操纵细胞功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES M PIPAS其他文献

JAMES M PIPAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES M PIPAS', 18)}}的其他基金

Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10401454
  • 财政年份:
    2020
  • 资助金额:
    $ 23.1万
  • 项目类别:
Analysis of cellular factors limiting productive JC virus infections
限制生产性 JC 病毒感染的细胞因素分析
  • 批准号:
    10312804
  • 财政年份:
    2020
  • 资助金额:
    $ 23.1万
  • 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10030247
  • 财政年份:
    2020
  • 资助金额:
    $ 23.1万
  • 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10196991
  • 财政年份:
    2020
  • 资助金额:
    $ 23.1万
  • 项目类别:
Manipulation of innate immunity by Polyomavirus T antigens
多瘤病毒 T 抗原操纵先天免疫
  • 批准号:
    10621762
  • 财政年份:
    2020
  • 资助金额:
    $ 23.1万
  • 项目类别:
Exploring viral infection with single cell transcriptomics
用单细胞转录组学探索病毒感染
  • 批准号:
    9285734
  • 财政年份:
    2016
  • 资助金额:
    $ 23.1万
  • 项目类别:
Exploring viral infection with single cell transcriptomics
用单细胞转录组学探索病毒感染
  • 批准号:
    9167182
  • 财政年份:
    2016
  • 资助金额:
    $ 23.1万
  • 项目类别:
Regulation of Transcription and Translation by Human Polyomaviruses
人类多瘤病毒的转录和翻译调控
  • 批准号:
    8849838
  • 财政年份:
    2014
  • 资助金额:
    $ 23.1万
  • 项目类别:
Regulation of Transcription and Translation by Human Polyomaviruses
人类多瘤病毒的转录和翻译调控
  • 批准号:
    8768850
  • 财政年份:
    2014
  • 资助金额:
    $ 23.1万
  • 项目类别:
Searching Environmental Metagenomes for Novel Infectious Cancer Agents (PQ12)
寻找环境宏基因组寻找新型传染性癌症病原体(PQ12)
  • 批准号:
    8382024
  • 财政年份:
    2012
  • 资助金额:
    $ 23.1万
  • 项目类别:

相似海外基金

Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
  • 批准号:
    10682185
  • 财政年份:
    2023
  • 资助金额:
    $ 23.1万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    475843
  • 财政年份:
    2022
  • 资助金额:
    $ 23.1万
  • 项目类别:
    Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
  • 批准号:
    474485
  • 财政年份:
    2022
  • 资助金额:
    $ 23.1万
  • 项目类别:
    Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10683329
  • 财政年份:
    2022
  • 资助金额:
    $ 23.1万
  • 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
  • 批准号:
    10481430
  • 财政年份:
    2022
  • 资助金额:
    $ 23.1万
  • 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
  • 批准号:
    nhmrc : 1196520
  • 财政年份:
    2021
  • 资助金额:
    $ 23.1万
  • 项目类别:
    Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10260234
  • 财政年份:
    2021
  • 资助金额:
    $ 23.1万
  • 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
  • 批准号:
    10548114
  • 财政年份:
    2021
  • 资助金额:
    $ 23.1万
  • 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
  • 批准号:
    10400318
  • 财政年份:
    2020
  • 资助金额:
    $ 23.1万
  • 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial)
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)
  • 批准号:
    449805
  • 财政年份:
    2020
  • 资助金额:
    $ 23.1万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了